Skip to main content

Perilipin-2/ADFP Antibody (2C5A3)

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-23486

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP2-23486SS

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human

Applications

ELISA, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # 2C5A3

Concentration

1.0 mg/ml

Product Summary for Perilipin-2/ADFP Antibody (2C5A3)

Immunogen

Partial recombinant human ADFP (between residues 200-437) expressed in E. coli [UniProt Q99541]

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Scientific Data Images for Perilipin-2/ADFP Antibody (2C5A3)

Western Blot: Perilipin-2/ADFP Antibody (2C5A3) [NBP2-23486]

Western Blot: Perilipin-2/ADFP Antibody (2C5A3) [NBP2-23486]

Western Blot: Perilipin-2/ADFP Antibody (2C5A3) [NBP2-23486] - Analysis of ADFP in (1) HEK293 and (2) PLIN2 hIgGFc transfected HEK293 cell lysate.
Immunocytochemistry/ Immunofluorescence: Perilipin-2/ADFP Antibody (2C5A3) [NBP2-23486]

Immunocytochemistry/ Immunofluorescence: Perilipin-2/ADFP Antibody (2C5A3) [NBP2-23486]

Immunocytochemistry/Immunofluorescence: Perilipin-2/ADFP Antibody (2C5A3) [NBP2-23486] - HepG2 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti-ADFP/Perilipin-2 (2C5A3) NBP2-23486 at a 1:50 dilution overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:500 dilution. Actin was counterstained using Phalloidin at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.
Immunohistochemistry: Perilipin-2/ADFP Antibody (2C5A3) [NBP2-23486]

Immunohistochemistry: Perilipin-2/ADFP Antibody (2C5A3) [NBP2-23486]

Immunohistochemistry: Perilipin-2/ADFP Antibody (2C5A3) [NBP2-23486] - Analysis of ADFP in paraffin-embedded human esophageal cancer tissues with DAB staining.

Applications for Perilipin-2/ADFP Antibody (2C5A3)

Application
Recommended Usage

ELISA

1:10000

Immunocytochemistry/ Immunofluorescence

1:10 - 1:100

Immunohistochemistry

1:200 - 1:1000

Immunohistochemistry-Paraffin

1:200 - 1:1000

Western Blot

1:500 - 1:2000
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Ammonium sulfate precipitation

Formulation

PBS, 0.5% proprietary protein stabilizer

Preservative

0.05% Sodium Azide

Concentration

1.0 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: Perilipin-2

Perilipin-2/Plin-2, also known as adipose differentiation-related protein (ADFP), ADRP, and adipophilin, is a member of the perilipin family of lipid droplet (LD) proteins that functions in lipid accumulation, lipid storage, and LD formation (1,2). Perilipin-2 is ubiquitously expressed and is the major LD protein of the liver (1-3). Human perilipin-2 is 437 amino acids (aa) in length with a theoretical molecular weight of 48 kDa (1,4). Human and mouse perilipin-2 share 81.8% sequence identity. One defining structural feature of perilipin-2 and other LD-related proteins is formation of amphipathic alpha helices (1,3,5). The perilipin-2 protein contains a PAT (perilipin A, ADRP, TIP47) domain, a 11-mer repeat motif, and a 4-helix bundle (1,5). The PAT domain has a role in triglyceride (TG) stabilization, the 11-mer repeat motif functions in cytoplasmic LD binding, and the 4-helix bundle facilitates membrane binding (5). Unlike LDs coated with other perilipin family members (e.g., perilipin-1 and perilipin-5), LDs coated with perilipin-2 are more permissive to lipolysis and protective of lipids and TGs (1-3). Studies have revealed that perilipin-2 knockout (KO) in mice is associated with resistance to fatty liver disease and diet-induced obesity (1). On the other hand, overexpression of perilipin-2 causes increased lipid and TG accumulation, which is a feature of many metabolic, cardiovascular, and age-related diseases (2). Additional research has found higher levels of perilipin-2 is associated with certain cancers such as colorectal cancer and renal carcinomas, and it may be a useful biomarker for detection (2). Though more research is needed, it is possible that inhibition or blocking of perilipin-2 may be a key strategy to combatting several pathologies (2).

References

1. Itabe H, Yamaguchi T, Nimura S, Sasabe N. Perilipins: a diversity of intracellular lipid droplet proteins. Lipids Health Dis. 2017;16(1):83. https://doi.org/10.1186/s12944-017-0473-y

2. Conte M, Franceschi C, Sandri M, Salvioli S. Perilipin 2 and Age-Related Metabolic Diseases: A New Perspective. Trends Endocrinol Metab. 2016;27(12):893-903. https://doi.org/10.1016/j.tem.2016.09.001

3. Sztalryd C, Brasaemle DL. The perilipin family of lipid droplet proteins: Gatekeepers of intracellular lipolysis. Biochim Biophys Acta Mol Cell Biol Lipids. 2017;1862(10 Pt B):1221-1232. https://doi.org/10.1016/j.bbalip.2017.07.009

4. Uniprot (Q99541)

5. Chong BM, Reigan P, Mayle-Combs KD, Orlicky DJ, McManaman JL. Determinants of adipophilin function in milk lipid formation and secretion. Trends Endocrinol Metab. 2011;22(6):211-217. https://10.1016/j.tem.2011.04.003

Alternate Names

ADFP, Adipophilin, Perilipin2, PLIN2

Entrez Gene IDs

123 (Human)

Gene Symbol

PLIN2

UniProt

Additional Perilipin-2 Products

Product Documents for Perilipin-2/ADFP Antibody (2C5A3)

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for Perilipin-2/ADFP Antibody (2C5A3)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...